No Benefit From Anthracyclines in ERBB2-Positive BC Treated with Dual ERBB2 Blockage
ERBB2/HER2-breast cancer (BC) is an aggressive form of BC that is associated with a poorer prognosis. Traditional treatment regimens for ERRB2/HER2 BC have included anthracyclines; however, recent evidence has questioned the necessity of adding these cardiotoxic agents to the chemotherapeutic regimen. Read more.

Link Between Breast Cancer and Viruses?
Studies have linked human papilloma virus (HPV) to the development of cervical cancer as far back as in the 1970s, but it was not until 2008 when it was determined that HPV caused cervical cancer. Others have looked for possible causative relationships between cancer and additional oncogenic viruses. Read more.

Assessing Fulvestrant and Trastuzumab in HER2-Positive Advanced BC
The optimal management of patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer (BC) is unclear. HER2+ BC is a heterogeneous disease, with about one-half of tumors also expressing HR+ status. Even within this group, there are various HR expressions, which further complicate therapeutic choices. Read more.